The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

Many skin conditions appear differently in melanated skin, leading to misdiagnosis and poor treatment. Understanding these ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two skin conditions ...

These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the ...

Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.